Jackpot for TiGenix' sepsis research

November 3, 2015 News BioVox

The biotech company TiGenix gets financial support in his search for a cure for severe sepsis due to pneumonia. The European Commission granted the Leuven-based company and its partners an amount of 5.4 million euros.

TiGenix is currently working on Cx611, a suspension of stem cells derived from adipose tissue that should be applied intravenously as a treatment for sepsis with organ failure, caused by severe pneumonia.

Up to now, there is no adequate treatment for severe sepsis. Treatment is mainly symptomatically with anti-inflammatory drugs and antibiotics. TiGenix refers to the current treatment as ‘palliative and supportive care’.

For this project, TiGenix partners with different research institutes from different countries. The grant is intended to fund a Phase II clinical study on nearly 180 patients.

The European Commission provides the grant through its Horizon 2020 plan, which aims to stimulate innovation and research in Europe. The project of TiGenix is one of the few clinical projects in Europe that acquired funds in this way.

Avatar photo

With a local focus and global reach, the news platform BioVox shares insights into the Benelux life sciences ecosystem with readers across the world. BioVox is an independent publisher, providing its community with quality content and first-row access to interesting breakthroughs and trends in biotech, medtech, agtech, pharma, and more. We shine a spotlight on the latest news and innovations from both our partners and community.

All posts


* indicates required

Intuit Mailchimp